Abstract
Haemophagocytic lymphohistiocytosis (HLH) is a severe, even fatal, inflammatory condition. Epstein-Barr virus (EBV) infection-associated HLH (EBV-HLH) is one of the most common types of secondary HLH. Etoposide is a key drug in HLH-94/04 regimen. We sought to identify the importance of etoposide in the initial treatment of EBV-HLH. Ninety-three patients with EBV-HLH of all ages admitted to our centre in 2017 were divided into two groups according to whether the initial treatment contained etoposide or not. The survival of the group whose initial therapy included etoposide (Group 1, 52 patients; 6-month survival rate 0·769) was significantly better than that of the group whose initial therapy did not include etoposide (Group 2, 41 patients; 6-month survival rate 0·269) (P<0·001). In patients aged <18years old, the survival of Group 1 patients was not significantly better than that of Group 2 patients (P=0·447), in contrast to patients aged ≥18years, where the survival of Group1 patients was significantly better than that of Group 2 patients (P<0·001). We concluded that including etoposide in the initial treatment of EBV-HLH patients can improve their prognosis, especially adult patients. This may be because that adult patients are recognized as "higher risk" patients.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
